Abstract

Epidermal growth factor receptor (EGFR) plays an important role in lung cell proliferation. Dimerization of EGFR family members and other receptor tyrosine kinases (RTKs) act as a vital controller for lung cell life cycle signals. Mutations in the kinase domain of EGFR may disorder the signaling networks and lead to cancer. Drug resistance occurs in several generations of EGFR drugs due to genetic mutations, and there is a very less understanding about the mechanism of EGFR-mutated drug resistance. In this work, we investigate the mechanism of wild type EGFR protein and its drug-sensitive and drug-resistant mutations. We performed molecular dynamics (MD) simulation for the 10-ns EGFR-drug mutant complex and investigated the structures’ geometrical properties. With features extracted by alpha shape modeling, different geometrical properties, such as matching rates of atom solid angles at interaction sites and centroid distances between interfacial atoms, were calculated to characterize the binding intensity. Wilcoxon rank sum test was applied to reveal the differences between mutations based on extracted properties. We have developed a framework that explains the drug resistance mechanism based on geometrical properties and binding free energy. Results revealed that drug-sensitive mutants have tighter interactions with corresponding RTK in the complex for all protein-drug systems, while drug-resistant mutants are bound looser. The extracted geometrical properties of the drug mutant complex help understand the drug response mechanism at atomic level.

Highlights

  • 2) MATCHING RATE OF INTERFACIAL ATOMS As we mainly focused on the Epidermal growth factor receptor (EGFR)-receptor tyrosine kinases (RTKs) interactions in the complexes, states of atoms on the interface between two peptide chains are essential

  • In this paper, we focused on interactions between EGFR and its RTK partner, as the dimerization between them plays a crucial role in the cellular signaling network

  • We established a set of models of drug-sensitive and drug-resistant EGFR mutants, dimerized them with EGFR and Insulin-like growth factor 1 receptor (IGF-1R), respectively

Read more

Summary

Introduction

A. BACKGROUND Lung cancer is the most deadly type of cancer, having the lowest survival rate among all types [1], [2]. Non-small cell lung carcinoma (NSCLC) is the primary type of lung cancer that covers about 85% of all the lung cancer cases, and it is an active research problem [3]. Epidermal growth factor receptor (EGFR), a member of the ErbB family, is a vital controller on signal pathways of cell proliferation [4], [5]. The extracellular domain of EGFR can be activated by binding to a ligand called a growth factor. A homodimer or a heterodimer of EGFR will

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call